• Willing to participate in the study and able to communicate consent during the consent process

• Willing and able to complete all applicable Registry/Screening Visit assessments

• Age ≥ 4 years

• Must have a single gene on the RD Rare Gene List which meets one of the Genetic Screening Criteria below based on a genetic report\* from a clinically certified lab (or from a research lab which has been approved by the study Genetics Committee):

⁃ Inheritance Pattern is Recessive and has at least 2 disease-causing variants which are homozygous or heterozygous in trans

⁃ OR

⁃ Inheritance Pattern is Recessive and has 2 disease-causing variants with unknown phase and meets all the following additional informatic criteria that is consistent with likely segregation in trans:

• Investigator confirms genotype and phenotype are consistent with autosomal recessive inheritance

• The 2 disease-causing variants have not been reported in cis in variant databases

• No additional potentially pathogenic variants were found on the gene (and the sequencing data for the gene were sufficiently robust to detect any additional potentially pathogenic variants)

• No potentially pathogenic variants were found in other common, likely candidate genes for the proposed condition

⁃ OR

⁃ Inheritance Pattern is Dominant, X-linked, or Mitochondrial and has at least 1 disease-causing variant

⁃ Both eyes must meet the following criteria at the Registry/Screening Visit to enroll into the genetic screening phase:

• Both eyes must have a clinical diagnosis of retinal dystrophy

• Both eyes must permit good quality photographic imaging (e.g., but not limited to, clear ocular media, adequate pupil dilation, stable fixation)